Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer

Phu N Tran\textsuperscript{1}  
Samuel J Klempner\textsuperscript{2,3}  
\textsuperscript{1}Division of Hematology/Oncology, University of California Irvine, Irvine, CA, \textsuperscript{2}Angeles Clinic and Research Institute, \textsuperscript{3}Cedars-Sinai Medical Center, Los Angeles, CA, USA

Abstract: Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the development of acquired resistance to EGFR inhibitors is universal and limits treatment efficacy. Over half of patients receiving first-generation EGFR inhibitors (erlotinib and gefitinib) develop resistance via the gatekeeper \textit{EGFR} T790M (\textit{EGFR}\textsubscript{T790M}) mutation, and therapies able to overcome T790M-mediated resistance have been an unmet need in NSCLC. Rociletinib (CO-1686) is a third-generation small-molecule EGFR inhibitor with potent activity against \textit{EGFR}\textsubscript{T790M} currently in advanced clinical development in NSCLC. Early clinical data suggested significant activity in \textit{EGFR}\textsubscript{-mutant NSCLC harboring T790M alterations. However, important questions regarding side-effect profile, comparability to competitor compounds, acquired resistance, EGFR-therapy sequencing, and combination therapies remain. Here, we review the available preclinical and clinical data for rociletinib, highlight the comparison to other third-generation EGFR inhibitors, and discuss resistance implications and future directions in NSCLC.

Keywords: lung cancer, rociletinib, EGFR, T790M, CO-1686, resistance, tyrosine-kinase inhibitor

Introduction

Non-small-cell lung cancer (NSCLC) remains the leading cause of global cancer-related mortality, with a 5-year survival rate of less than 20% in US patients.\textsuperscript{1} The discovery of activating mutations in \textit{EGFR} and subsequent development of small-molecule EGFR inhibitors revolutionized the management of \textit{EGFR}-mutant NSCLC. Activating mutations in \textit{EGFR} are detected in approximately 30%–40% of NSCLC in Asian patients and 10% of NSCLC in Caucasian patients.\textsuperscript{2} An in-frame deletion in exon 19 (exon19del) and the L858R point mutation in exon 21 constitute nearly 90% of known EGFR alterations, though more sensitive and comprehensive methods continue to identify new therapeutically relevant EGFR alterations.\textsuperscript{3,4} The IPASS and EURTAC trials established and confirmed the benefit of the first-generation EGFR tyrosine-kinase inhibitors (TKIs) gefitinib and erlotinib over chemotherapy in patients harboring sensitizing EGFR alterations.\textsuperscript{5,6} Despite response rates of 50%–70% for first-generation EGFR inhibitors in EGFR exon19del and L858R patients, the median progression-free survival (PFS) is 9–13 months, highlighting the need for additional therapies.\textsuperscript{6–8}
Progression-biopsy samples from patients no longer responding to erlotinib and gefitinib elucidated the landscape of resistance to first-generation EGFR TKIs. Resistance mechanisms can be classified broadly into target modification, bypass signaling, and phenotypic transformation. Target modification via development of an \( \text{EGFR}^{T790M} \) mutation is responsible for 50%–60% of acquired resistance to first-generation inhibitors. \( \text{EGFR} \)-activating mutations, such as L858R, G719S, and exon 19 deletions decrease the affinity of EGFR for adenosine triphosphate (ATP), rendering them more susceptible to competitive inhibition by TKIs relative to wild-type (WT) \( \text{EGFR} \) (\( \text{EGFR}^{\text{WT}} \)). The threonine (T) at position 790 (T790) lies near the passage to the kinase hydrophobic back pocket (gatekeeper), and substitution with the bulkier methionine (M) (T790M) mediates resistance partly by inducing steric hindrance in the ATP-binding pocket and preventing inhibitor binding. Additionally, the \( \text{cis} \) (same allele) addition of T790M increases the affinity for ATP of mutant \( \text{EGFR} \), restoring it to the level of the WT kinase, leading to reduced TKI efficacy. Beyond a T790M-mediated mechanism, preclinical work and progression biopsies from patients on first-generation EGFR TKIs have revealed \( \text{MET} \) amplification, \( \text{ERBB2} \) amplification, SCLC transformation, epithelial–mesenchymal changes, and acquired RET rearrangements as resistance mechanisms. Tumor heterogeneity, clonal evolution, and the role of small populations with de novo \( \text{EGFR}^{T790M} \) alterations are also emerging as an important biologic underpinning to clinical resistance in \( \text{EGFR} \)-mutant NSCLC.\(^{19-21}\)

Prior to the advent of third-generation EGFR inhibitors, patients found to harbor an \( \text{EGFR}^{T790M} \) mutation after progression on first-generation EGFR inhibitors had limited options, including standard second-line chemotherapy, platinum doublets, and EGFR TKIs combined with chemotherapy.\(^{22-24}\) The second-generation EGFR TKIs, including afatinib, a highly selective and irreversible pan-HER inhibitor, demonstrated preclinical activity in \( \text{EGFR}^{T790M} \) models; however, in the Lux-Lung 4 trial, 62 patients with advanced NSCLC who progressed on either erlotinib and/or gefitinib received afatinib with limited benefit.\(^{25-27}\) A single patient with \( \text{EGFR}^{T790M} \) achieved stable disease for 9 months. The addition of cetuximab to afatinib improved the overall response rate (ORR) to 29% (32% RR in T790M+ and 25% in T790M- tumors) with a median PFS of 4.7 months.\(^{28}\) However, this regimen was associated with significant cutaneous, mucosal, and gastrointestinal toxicities, limiting its clinical impact. More recently, the addition of bevacizumab to erlotinib has demonstrated activity in \( \text{EGFR}^{T790M} \), but ongoing trials are needed for confirmation.\(^{29}\) Given the underwhelming activity of earlier approaches, novel compounds capable of overcoming \( \text{EGFR}^{T790M} \) remain a significant unmet need in NSCLC.

### Rociletinib characterization and preclinical development

Rociletinib (CO1686) is a potent 5-CF, 2,4-diaminopyrimidine-based molecule that consists of a reactive acrylamide group, an aminopyrimidine group, and a piperazine ring.\(^{30}\) The acrylamide group forms a covalent bond with cysteine (C) 797 in the ATP-binding pocket of the EGFR kinase and is responsible for the irreversible inhibition. The aminopyrimidine binds to the hinge residue methionine (M) 793 through hydrogen bonding, and the 5-substituent of the aminopyrimidine points to the gatekeeper residue (methionine in T790M) and forms strong hydrophobic interaction.\(^{31}\) In the \( \text{EGFR}^{\text{WT}} \) kinase, the smaller threonine (T) residue at position 790 results in weaker hydrophobic forces, and contributes to the selectivity for the T790M mutant over \( \text{EGFR}^{\text{WT}} \).

In preclinical kinase assays, compound \( \text{EGFR}^{L858R/T790M} \) mutant kinases were 22-fold more sensitive to rociletinib versus \( \text{EGFR}^{\text{WT}} \), with inactivation rate constant to binding constant ratios of \( 2.41 \times 10^4 \text{ M}^{-1} \text{S}^{-1} \) and \( 1.12 \times 10^4 \text{ M}^{-1} \text{S}^{-1} \), respectively. In the in vitro kinase assay, the half-maximal inhibitory concentration (IC\(_{50}\)) of rociletinib for \( \text{EGFR}^{L858R/T790M} \) and \( \text{EGFR}^{\text{WT}} \) were <0.51 nM and 6 nM, respectively. Cellular growth assays reported IC\(_{50}\) in the 100–140 nM range (Table 1). Kinase profiling demonstrated activity against \( \text{EGFR} \) exon 19 deletion, T790M, L858R/T790M, and L858R, with weak inhibition of other kinases, including FAK, CHK2, ERBB4, and JAK3. In \( \text{EGFR}^{T790M} \), rociletinib demonstrated dose-dependent tumor response and improved activity compared to erlotinib and afatinib, a finding confirmed in transgenic mouse studies.\(^{32}\)

Mice carrying \( \text{EGFR}^{L858R} \) mutant tumors had responses to both erlotinib and rociletinib, while mice carrying \( \text{EGFR}^{L858R/T790M} \) tumors displayed responses to rociletinib only. Overall, preclinical studies indicate strong efficacy signals with favorable early toxicity profile, warranting further clinical investigation.

### Rociletinib in NSCLC: clinical activity

A Phase I/II rociletinib clinical trial investigated the safety, maximum tolerated dose, recommended Phase II dose,
Table 1 Comparison of the preclinical and clinical features of small-molecule EGFR inhibitors with activity against the EGFR<sup>T790M</sup>
resistance mutation

<table>
<thead>
<tr>
<th>Compound</th>
<th>EGFR&lt;sup&gt;T790M&lt;/sup&gt; IC&lt;sub&gt;50&lt;/sub&gt; (nM)*</th>
<th>Study</th>
<th>Results</th>
<th>Common or unique toxicities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rociletinib</td>
<td>100–140</td>
<td>Phase I/II</td>
<td>T790M+: RR 59%,&lt;sup&gt;a&lt;/sup&gt; DCR 93%, PFS 13.1 months</td>
<td>Hyperglycemia, prolonged QTc</td>
</tr>
<tr>
<td>(CO1686)</td>
<td></td>
<td></td>
<td>T790M: RR 29%, DCR 59%</td>
<td></td>
</tr>
<tr>
<td>Osimertinib</td>
<td>11–40</td>
<td>Phase I</td>
<td>ORR 51%</td>
<td>Common AEs: diarrhea, rash, nausea; severe AEs included pneumonitis, prolonged QTc</td>
</tr>
<tr>
<td>(AZD9291)</td>
<td></td>
<td></td>
<td>T790M: RR 61%, PFS 9.6 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>T790M: RR 21%, PFS 2.8 months</td>
<td></td>
</tr>
<tr>
<td>HM61713</td>
<td>10–26</td>
<td>Phase I/II</td>
<td>PR 62%, DCR 91%</td>
<td>Common AEs: diarrhea, skin toxicities, poor appetite DLTs: diarrhea, transaminitis, and elevated lipase</td>
</tr>
<tr>
<td>EGF816</td>
<td>9–25</td>
<td>Phase I</td>
<td>ORR 54.5%, DCR 86.4%</td>
<td>Common AEs: diarrhea, stomatitis, rash DLTs: rashes, AKI</td>
</tr>
<tr>
<td>ASP8273</td>
<td>14</td>
<td>Phase I</td>
<td>PR 28%, DCR 84%</td>
<td>Common AEs: N, diabetes DLTs: anorexia, hyponatraemia</td>
</tr>
</tbody>
</table>

Notes: *As reported in the original publication,<sup>29</sup> and subsequently revised down; *range reported to reflect testing in differing cell lines and compound mutants L858R/ T790M and exon19del/T790M.

Abbreviations: AKI, acute kidney injury; IC<sub>50</sub>, half-maximal inhibitory concentration (to achieve 50% inhibition in cellular growth assays); N, nausea; RR, response rate; AEs, adverse events; DCR, disease-control rate; PFS, progression-free survival; QTc, corrected QT; ORR, overall response rate; DLTs, dose-limiting toxicities; PR, partial response.

and early antitumor activity in patients with advanced EGFR-mutated NSCLC who had been previously treated and progressed on either first- or second-generation EGFR TKIs.<sup>31</sup> This study enrolled 130 patients at ten institutions, and patients received oral rociletinib on daily, twice-daily, or thrice-daily dosing schedules. The maximum tolerated dose was not reached, and the most consistently effective dose was 900 mg twice daily in the initial free-base formulation. The study subsequently switched to a newer rociletinib hydrobromic acid form, which had improved bioavailability: 92 of 130 patients received therapeutic doses and were included in the efficacy analysis. Among 46 patients harboring EGFR<sup>T790M</sup> mutations, the investigator-assessed RR was 59% and disease-control rate (DCR) 93% (Table 1).<sup>33</sup> RRs were similar between patients with original exon19del and L858R EGFR mutations. The median PFS in the T790M− subset was 13.1 months at the time of analysis. In EGFR-mutant but T790M− (n=17) patients, the RR was 29% and DCR 59%. The initially reported data showed comparable activity to the simultaneously published competitor compound osimertinib (AZD9291).<sup>34</sup> The most common reported toxicities from the Phase I/II study included nausea (35%), fatigue (24%), diarrhea (22%), and poor appetite (20%). Although rociletinib was generally well tolerated in early studies, several interesting side effects were noted, including hyperglycemia, corrected QT (QTc) prolongation (12%), and development of cataracts. Hyperglycemia occurred in 43% of patients, caused by a rociletinib metabolite (M502) that inhibited insulin-like growth factor (IGF)-receptor and insulin-receptor kinases and induced glucose intolerance in rodents in preclinical studies.<sup>33,35</sup> Rociletinib quickly undergoes amide hydrolysis into the metabolite M502 (69%), which can be converted to the M460 (3%) metabolite by the same reaction.<sup>36</sup> Time-dependent exposure to M502 and M460 is responsible for inducing hyperglycemia and QTc prolongation, respectively. While the half-life of rociletinib is 3.7 hours, the half-lives of M502 and M460 are up to 20 hours and 51 hours, respectively. Both M502 and M460 are acetylated to subsequent metabolites by N-acetyltransferase (NAT2).<sup>36</sup> Interestingly, NAT2 exhibits significant polymorphisms across different racial/ethnic groups, leading to different rates of acetylation (eg, slow versus rapid acetylators).<sup>37</sup> Asians are generally faster acetylators, while Caucasians, Hispanics, and African-Americans are slower acetylators. Therefore, Asian populations may theoretically experience fewer metabolite-mediated toxicities from rociletinib. The current published data do not report stratification of RRs or toxicities by race/ethnicity. Overall, there was no study discontinuation due to toxicities, though dose reduction was needed in 44 of 92 (48%) patients.

The clinical activity of rociletinib was refined in an updated release from Clovis Oncology, in which the confirmed RR was revised down to 28% for the 79 patients in the 500 mg-dose arm and 34% for the 170 patients in the 625 mg-dose group. As reported, a significant portion of the initially described responses were not confirmed on subsequent imaging, largely due to disease progression (commonly brain metastases).<sup>38</sup> Stratification by T790M status was not reported in conjunction with this release. In the updated release, hyperglycemia and prolonged QTc remained important treatment-related toxicities, with rates of grade 3–4 adverse events at 34% and 33%, respectively.<sup>38</sup> Additionally, cases of potentially life-threatening arrhythmias, including torsades de pointes (n=1), ventricular arrhythmia (n=4),
atrial fibrillation (n=5), and supraventricular tachycardia (n=4), were observed. The toxicity profile was similar across the dose range (500–1,000 mg twice daily), although the proportion of patients requiring three or four dose reductions was higher for patients given 625 mg twice daily or higher.

In April 2016, based on available data, an independent panel of experts voted 12-1 against giving rociletinib an accelerated approval and recommended waiting for the results and safety analysis from the ongoing Tiger 3 trial, comparing rociletinib to chemotherapy in both T790M+ and T790M- patients with acquired TKI resistance after failure of one or more previous EGFR TKIs and platinum-doublet chemotherapy.

### Additional third-generation EGFR inhibitors

Several other EGFR TKIs able to overcome the EGFR\textsuperscript{T790M} resistance mutation are in advanced stages of development, and on November 13, 2015 the US Food and Drug Administration (FDA) approved osimertinib (AZD9291) for patients with EGFR\textsuperscript{T790M} NSCLC who have progressed on prior EGFR TKI therapy. AZD9291 is a structurally distinct mutant EGFR-selective monoanilinopyrimidine that covalently binds the EGFR\textsuperscript{L858R/T790M} cysteine at position 797.\textsuperscript{39} In a large Phase I trial, the ORR was 51% in patients who had failed prior EGFR TKIs.\textsuperscript{40} In patients with centrally confirmed EGFR\textsuperscript{T790M}, RR and median PFS were 61% and 9.6 months (95% confidence interval [CI]: 8.3–not reached), respectively. In contrast, the RR and median PFS were 21% (95% CI: 12–34) and 2.8 months (95% CI: 2.1–4.3) for patients with EGFR\textsuperscript{T790M}- tumors (Table 1). AZD9291 was generally well tolerated, with common toxicities including diarrhea (47%), nausea (25%), rash (21%), anorexia (20%), xerosis (20%), pruritus (19%), and fatigue (17%). There were six patients with hyperglycemia, and eleven patients had non-clinically significant QTc prolongation. Six patients developed pneumonitis-like toxicity requiring drug discontinuation.\textsuperscript{40}

HM61713 (BI1482694) is an irreversible EGFR\textsuperscript{T790M} inhibitor with potent and selective inhibition in EGFR-mutant models (Table 1).\textsuperscript{41} Results from an ongoing Phase I/II HM-EMSI-101 study evaluating the safety and efficacy of HM61713 on 173 patients with centrally confirmed T790M- NSCLC who had failed prior TKIs were presented at the 2015 American Society of Clinical Oncology Annual Meeting.\textsuperscript{42} Most common adverse events included diarrhea, rash, skin exfoliation, nausea, pruritus, decreased appetite, and dry skin. Dose-limiting toxicities included abdominal pain, diarrhea, idiosyncratic drug reaction, transaminitis, and elevated lipase. Over half (58.5%) of patients achieved a partial response (PR), and the DCR was 97.1% in a subset of 37 evaluable patients. Updated interim data presented at the European Society for Medical Oncology meeting in December 2015 showed PR and DCR rates of 62% and 91%, respectively, among 69 evaluable patients.\textsuperscript{43,44} Consequently, the FDA granted HM61713 breakthrough-therapy designation, and the global second-line ELUXA 1 (HM-EMSI-202) study is ongoing (NCT02485652).

EGF816 is an irreversible EGFR TKI that has nanomolar inhibitory potency against L858R/T790M+ and ex19del/T790M+, with up to 60-fold selectivity over EGFR\textsuperscript{WT} in vitro (Table 1). EGF816 suppresses phosphorylated EGFR levels and inhibits proliferation of cells harboring EGFR\textsuperscript{T790M} mutations at IC\textsubscript{50} of 3 nM and 25 nM, respectively.\textsuperscript{45} In an ongoing Phase I multicenter dose-escalation study in advanced NSCLC patients with confirmed EGFR\textsuperscript{T790M} status, the most common reported toxicities were diarrhea (25%), stomatitis (22.5%), rash (17.5%), and pruritus (15%) in 40 patients who were evaluated for safety. Among 22 evaluable patients, the ORR and DCR were 54.5% and 86.4%, respectively.\textsuperscript{46} Other trials are investigating the efficacy and safety of combining EGF816 and INC280 (MET inhibitor) (NCT02335944) and EGF816 with the anti-PD1 antibody nivolumab (NCT02323126).

The third-generation EGFR TKI ASP8273 has activity in T790M+ tumors with IC\textsubscript{50} values of 8–33 nM (Table 1).\textsuperscript{47} ASP8273 selectively inhibits mutant EGFR by covalently binding to C797 (like rociletinib), and has demonstrated complete tumor regression in mouse xenograft models. Importantly, ASP8273 has demonstrated activity in a cell line resistant to AZD9291 and CO1686.\textsuperscript{48} In a Phase I study, 35 previously treated NSCLC patients with activating EGFR mutations were enrolled, and side effects were generally mild, including nausea (25.7%) and diarrhea (17.1%).\textsuperscript{49} Dose-limiting toxicities at 400 mg were grade 3 hyponatremia and grade 3 anorexia. Hyperglycemia and QTc prolongation were not observed. Among 25 subjects evaluable for response, seven (28%) patients had PR and 15 (56%) achieved stable disease. Astellas is investigating the role of ASP8273 as first-line therapy compared to erlotinib or gefitinib in an ongoing Phase III trial (NCT02588261). Other compounds in earlier stages of development have shown comparable early efficacy, and therapeutic choices are likely to be impacted by side-effect profiles, PFS, and ultimately overall survival data.

### Rociletinib resistance

Despite the reported clinical efficacy of the third-generation EGFR inhibitors, acquired resistance is expected to be
universal, and has recently been described. The acquisition of a substitution in EGFR at serine (S) 797 for cysteine (C) (C797S) causes resistance to C01686, AZD9291, and HM61713 in patients. The C797S substitution interferes with the covalent bond formation between the cysteine residue of the acrylamide group of rociletinib, reducing inhibitor binding and efficacy, and would be predicted as a vulnerability. Despite limited data, the C797S mutation appears more common in exon19del/T790M+ tumors, and the C797S mutation was observed in seven of ten exon19del/T790M+ patients but none of the six patients with L858R/T790M+ mutations who progressed on AZD9291. Interestingly, a small series suggests that osimertinib may be able to induce response after progression on rociletinib, highlighting differences between these two compounds.

Recently, Niederst et al indicated that the genomic configuration (cis versus trans) of the T790M and C797S mutations could impact response to TKI therapy. Specifically, when the mutations were in trans (on different alleles), the combination of first- and third-generation EGFR TKIs abrogated the resistance. If the mutations were in cis (on the same allele), then the cells were resistant to a combination of EGFR TKIs. While this level of genomic detail is not yet used to guide therapies, one can appreciate how cis and trans conformation may impart therapeutic sequence.

EGFR mutations L718Q and K844V, which appear to create steric hindrance with rociletinib (but not AZD9291) have been observed in vitro, and may ultimately impact clinical treatment choices. Quinazoline-based EGFR inhibitors, such as gefitinib and afatinib, are able to overcome the C797S, L718Q, and K844V alterations, and appear active in T790M+ tumors harboring these rociletinib-resistant mutations. In models studying compound resistance mutations involving EGFR\(^{L858R/T790M}\) with concurrent C797S, L718Q, or K844V alterations, the compound mutants were resistant to all known EGFR inhibitors in vitro. Cetuximab appeared to retain some activity in a subset of cells with tertiary EGFR\(^{L858R/T790M/C797S}\) mutations, but further in vivo studies are required to confirm this observation.

Treatment of T790M+ patients with rociletinib may also result in “loss” of the T790M+ population or selection/emergence of T790 WT clones, as has been observed in progression samples from six of 12 patients in one series. This phenomenon was also observed in some T790M+ patients who had progressive disease on AZD9291. Other mechanisms of rociletinib resistance include histologic transformation and bypass resistance similar to other EGFR TKIs. Walter et al reported rociletinib-resistant cells exhibited a spindle-like morphology, overexpressed genes involved in epithelial–mesenchymal transition, had higher level of basal phosphorylated AKT, and were sensitive to a combination of the AKT inhibitors MK2206 and GDC0068. SCLC transformation was observed in two of 12 patients who had progression on rociletinib.

Resistance observations have important implications for sequential EGFR TKI therapy. For example, treatment of EGFR-mutant NSCLC tumor cells with reversible quinazoline-based TKIs leads mainly to secondary T790M mutation, whereas up-front treatment with T790M-potent EGFR TKIs prevents emergence of the \(EGFR^{T790M}\) mutation and shifts toward resistance mechanisms involving IGF1-receptor and mitogen-activated protein kinases (MAPK)-pathway activation. These preclinical models suggest that combining T790M-potent EGFR TKIs with either MEK or IGF1T inhibitors may prevent/delay the emergence of drug-resistant clones. However, it may be advantageous to begin with first-generation inhibitors, given the emerging efficacy of third-generation compounds. The wide array of potential resistance mechanisms to T790M-active EGFR TKIs underscores the importance of sequential biopsies and extended molecular testing to identify the underlying mechanism of resistance and guide subsequent therapy.

**Conclusion and future directions**

Here, we have provided an overview of the preclinical and clinical data for rociletinib (CO1686) in NSCLC (Tables 1 and 2). In the rapidly evolving landscape of EGFR-mutant, T790M+ NSCLC, rociletinib showed significant early promise, but the revised response and toxicity data highlight the importance of rigorous prospective trials to validate early data in drug development. Although direct head-to-head comparison among third-generation inhibitors is not available, the absolute RR and side-effect profile of rociletinib has raised concerns about the optimal pathway forward. Data addressing NAT2-polymorphism impact on rociletinib response and toxicity may suggest populations that derive benefit with limited toxicity.

**Table 2 Structural and pharmacologic properties of the third-generation EGFR inhibitor rociletinib**

<table>
<thead>
<tr>
<th>Rociletinib property/feature</th>
<th>Molecular formula and weight C(<em>{27})H(</em>{33})F(<em>{3})N(</em>{2})O(_{3}), (555.55 g/mol)</th>
<th>Pharmacokinetics</th>
<th>Biological efficacy</th>
<th>Metabolism</th>
<th>Metabolites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete resistance</td>
<td>C(<em>{27})H(</em>{33})F(<em>{3})N(</em>{2})O(_{3}), (555.55 g/mol)</td>
<td>Maximum serum concentration 2.41 μg/mL</td>
<td>Effective: exon 19 deletion, L858R, T790M</td>
<td>Fecal elimination 85.2% (65.2% unchanged)</td>
<td>M502 (69%), M544 (23%), and M460 (3%)</td>
</tr>
</tbody>
</table>
Incorporation of early response biomarkers, including circulating tumor DNA for EGFR<sup>TM90M</sup> burden are likely to further refine optimal patient populations. Early toxicity-recognition and management strategies may reduce the hyperglycemia rates in the ongoing rociletinib studies. Ultimately, larger-outcome data sets from Phase II and III studies will define the role of rociletinib in EGFR<sup>TM90M</sup> NSCLC.

Acknowledgment

The authors would like to recognize the important contributions from researchers whose work could not be cited due to space constraints.

Disclosure

The authors report no conflicts of interest in this work. Subsequent to the acceptance of this manuscript Clovis Oncology stopped further clinical development of rociletinib.

References


